OKYO Pharma Limited

EMMLD

GG00BMFG5F62

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 02:00:01 01/06/2024 am IST			5-day change	1st Jan Change
1.49 ^USD	+7.19%		+12.88%	-15.82%

22/03	H.C. Wainwright Adjusts Price Target on OKYO Pharma to $7 From $6, Maintains Buy Rating	MT
22/03	OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101	CI

OKYO Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2023

August 15, 2023 at 04:20 pm IST

OKYO Pharma Limited reported earnings results for the full year ended March 31, 2023. For the full year, the company reported net loss was GBP 13.27 million compared to GBP 5.43 million a year ago. Basic loss per share from continuing operations was GBP 0.61 compared to GBP 0.36 a year ago.

Latest news about OKYO Pharma Limited

H.C. Wainwright Adjusts Price Target on OKYO Pharma to $7 From $6, Maintains Buy Rating	22/03	MT
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101	22/03	CI
OKYO Pharma Limited to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial	20/03	CI
Sector Update: Health Care Stocks Mixed in Afternoon Trading	10/02	MT
Sector Update: Health Care	10/02	MT
OKYO Pharma Rising After FDA Approves Phase 2 Trial of Prospective Treatment for Cornea Eye Pain	09/02	MT
Okyo Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain	09/02	CI
OKYO Pharma Limited Announces Appointment of Scientific Advisory Board	31/01	CI
OKYO Pharma Limited Reports Positive Safety and Efficacy Results in Its Phase 2, Randomized, Double-Masted, Placebo-Controlled Trial Evaluating the Safety and Efficacy of OK-101 Ophthalmic Solution in Patients with Dry Eye Disease	08/01	CI
Okyo Pharma Limited Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit	04/12	CI
HC Wainwright Initiates Coverage on OKYO Pharma with Buy Rating, $4 Price Target	02/11	MT
Sector Update: Health Care Stocks Lean Lower Premarket Monday	09/23/09	MT
OKYO Pharma Submits Investigational New Drug Application for OK-101 in Neuropathic Corneal Pain	09/23/09	MT
Okyo Pharma Limited Announces Filing of an Investigational New Drug Application for Ok-101 to Treat Neuropathic Corneal Pain	09/23/09	CI
OKYO Pharma Limited Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease	05/23/05	CI
Traders Digest Fresh Batch of Data, Stifling US Equity Futures Pre-Bell	15/23/15	MT
Top Premarket Decliners	15/23/15	MT
Sector Update: Health Care Stocks Rising Late Afternoon	15/23/15	MT
Sector Update: Health Care Stocks Rising in Afternoon Trading	14/23/14	MT
OKYO Pharma Prices $4 Million Share Offering	14/23/14	MT
Top Premarket Decliners	14/23/14	MT
OKYO Pharma Plans Share Offering; Stock Down After-Hours	14/23/14	MT
Top Premarket Decliners	13/23/13	MT
Okyo Pharma Limited Completes Enrollment in Phase 2 Clinical Trial of Ok-101 to Treat Dry Eye Disease	08/23/08	CI
Top Premarket Decliners	31/23/31	MT

Chart OKYO Pharma Limited

Duration

Period

More charts

Company Profile

OKYO Pharma Limited is a United Kingdom-based clinical stage biopharmaceutical company developing therapies for the treatment of dry eye disease (DED) and neuropathic corneal pain (NCP). The Company is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. Its research program is focused on a novel G Protein-Coupled Receptor (GPCR). The Company is developing OK-101, its lead preclinical product candidate, for the treatment of DED. OK-101 is focused on keratoconjunctivitis sicca, commonly referred to as DED, which is a multifactorial disease caused by an underlying inflammation resulting in the lack of lubrication and moisture in the surface of the eye. The Company also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. It is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.

Sector

Pharmaceuticals

Calendar

30/07/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.49 USD

Average target price

7 USD

Spread / Average Target

+369.80%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
OKYO PHARMA LIMITED	-15.82%	4.95Cr
CSL LIMITED	-2.29%	8.99TCr
SAMSUNG BIOLOGICS CO.,LTD.	-3.95%	3.76TCr
BIOGEN INC.	-13.07%	3.28TCr
UCB	+63.05%	2.65TCr
BIOMARIN PHARMACEUTICAL INC.	-22.14%	1.43TCr
INCYTE CORPORATION	-7.96%	1.3TCr
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.33%	1.19TCr
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-46.33%	1.08TCr
SWEDISH ORPHAN BIOVITRUM AB	+5.77%	911.12Cr

Biopharmaceuticals